Replay available

Viking Therapeutics, Inc. (0VQA) Q3 2025 Earnings Call

Viking Therapeutics, Inc. (LSE: 0VQA) Q3 2025 earnings conference call, held 2025-10-22. Replay captured from the company's public earnings webcast.

Wed, October 22, 2025 at 4:30 PMendedReplay
Viking Therapeutics, Inc. (0VQA) Q3 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Stephanie Diaz

Manager of Investor Relations

Brian Leon

President and Chief Executive Officer

Greg Zanti

Chief Financial Officer

Replay transcript excerpt

Welcome to the Viking Therapeutics third quarter 2025 financial results conference call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press the star key followed by one on your touchtone phone. If anyone has difficulty hearing the conference, please press star zero for operator assistance. As a reminder, this conference call is being recorded today, October 22, 2025. I would now like to turn the conference over to Vikings Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie. Hello, and thank you all for participating in today's call. Joining me today is Brian Leon, Vikings President and CEO, and Greg Zanti, Vikings CFO. Before we begin, I'd like to caution that comments made during this conference call today, October 22, 2025, will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Vikings' expectations regarding its development activities, timelines, and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely, and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as of today's date, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings for the Securities and Exchange Commission concerning these and other matters. I'll now turn the call over to Brian Lynn for his initial comments. Thanks, Stephanie, and good afternoon to everyone listening in by phone or on the webcast. Today...

More from Viking Therapeutics, Inc.